Equator tablets 10mg + 20mg, No. 30

Essential hypertension (patients for whom combination therapy is indicated).

Inside, regardless of the meal. The recommended dose is 1 table. EquatorЃ daily. The maximum daily dose is one tablet of EquatorЃ.

Patients with renal impairment. To determine the optimal initial and maintenance dose for patients with renal insufficiency, the dose must be titrated and determined individually, using lisinopril and amlodipine separately. EquatorЃ is indicated only for those patients in whom the optimal maintenance dose of lisinopril and amlodipine is titrated to 20 and 5 mg (or 5 and 10 mg, or 20 and 10 mg), respectively. During treatment with EquatorЃ, it is necessary to monitor renal function, potassium and sodium levels in blood serum. In case of deterioration of renal function, taking the drug EquatorЃ should be canceled and replaced with lisinopril and amlodipine in adequate doses.

Patients with hepatic impairment. The excretion of amlodipine may be slowed down in patients with impaired liver function. Clear recommendations on the dosage regimen in such cases have not been established, therefore, EquatorЃ should be prescribed with caution in patients with hepatic impairment.

Elderly patients (over 65 years old). In clinical studies, no age-related changes in efficacy or safety profile were found for amlodipine and lisinopril. To determine the optimal maintenance dose, it is necessary to determine the dosage regimen individually, using separately lisinopril and amlodipine. EquatorЃ is indicated only for those patients in whom the optimal maintenance dose of lisinopril and amlodipine is titrated to 20 and 5 mg (or 5 and 10 mg, or 20 and 10 mg), respectively.

hypersensitivity to lisinopril or other ACE inhibitors;

hypersensitivity to amlodipine or other dihydropyridine derivatives;

hypersensitivity to other components of the drug;

history of Quincke's edema, incl. against the background of the use of ACE inhibitors;

hereditary or idiopathic angioedema;

hemodynamically significant stenosis of the aorta or mitral valve or hypertrophic cardiomyopathy;

severe arterial hypotension (SBP less than 90 mm Hg);

cardiogenic shock;

unstable angina (with the exception of Prinzmetal's angina);

heart failure after acute myocardial infarction (within the first 28 days);

pregnancy;

breastfeeding period;

age up to 18 years (due to the lack of data on the effectiveness and safety of the drug in this age group).

With care: severe renal dysfunction; bilateral stenosis of the renal arteries or stenosis of an artery of a solitary kidney with progressive azotemia; condition after kidney transplantation; azotemia; hyperkalemia; primary hyperaldosteronism; liver dysfunction; arterial hypotension; cerebrovascular diseases (including cerebral circulation insufficiency); coronary heart disease; coronary insufficiency; sick sinus syndrome (severe bradycardia, tachycardia); chronic heart failure of non-ischemic etiology of III Ц IV functional class according to NYHA classification; aortic stenosis; mitral stenosis; acute myocardial infarction (and within 1 month after myocardial infarction); autoimmune systemic diseases of the connective tissue (including scleroderma, systemic lupus erythematosus);oppression of bone marrow hematopoiesis; diabetes; diet with restriction of table salt; hypovolemic conditions (including as a result of diarrhea, vomiting); elderly age; hemodialysis using high-flow, high-permeability dialysis membranes (AN69Ѓ).